STAT5B and B-cell non-Hodgkin lymphoma: In comparison, STAT5A shows favorable prognostic associations in breast cancer but detrimental effects in hematologic malignancies [5], whereas STAT5B appears predominantly tumor-suppressive across epithelial cancers and protective in B-cell lymphomas.